Biovail faces U.S. investigation over Cardizem
TORONTO |
TORONTO Feb 1 (Reuters) - Biovail Corp BVF.TO BVF.N said on Friday that it is being investigated by a U.S. Federal grand jury concerning the 2003 commercial launch of its Cardizem LA heart drug.
The company said the action could lead to civil or criminal charges and it was cooperating with the probe. ($1=$1.00 Canadian) (Reporting by Scott Anderson; editing by Janet Guttsman)
- Tweet this
- Link this
- Share this
- Digg this
- Reprints
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.
Follow Reuters